429 related articles for article (PubMed ID: 29593043)
1. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
2. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
3. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
[TBL] [Abstract][Full Text] [Related]
4. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
5. Lassa Virus, but Not Highly Pathogenic New World Arenaviruses, Restricts Immunostimulatory Double-Stranded RNA Accumulation during Infection.
Mateer EJ; Maruyama J; Card GE; Paessler S; Huang C
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051278
[TBL] [Abstract][Full Text] [Related]
6. E3 Ligase ITCH Interacts with the Z Matrix Protein of Lassa and Mopeia Viruses and Is Required for the Release of Infectious Particles.
Baillet N; Krieger S; Carnec X; Mateo M; Journeaux A; Merabet O; Caro V; Tangy F; Vidalain PO; Baize S
Viruses; 2019 Dec; 12(1):. PubMed ID: 31906112
[TBL] [Abstract][Full Text] [Related]
7. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
Lukashevich IS; Patterson J; Carrion R; Moshkoff D; Ticer A; Zapata J; Brasky K; Geiger R; Hubbard GB; Bryant J; Salvato MS
J Virol; 2005 Nov; 79(22):13934-42. PubMed ID: 16254329
[TBL] [Abstract][Full Text] [Related]
8. NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression.
Russier M; Reynard S; Tordo N; Baize S
Eur J Immunol; 2012 Jul; 42(7):1822-32. PubMed ID: 22585682
[TBL] [Abstract][Full Text] [Related]
9. Infection of Human Endothelial Cells with Lassa Virus Induces Early but Transient Activation and Low Type I IFN Response Compared to the Closely-Related Nonpathogenic Mopeia Virus.
Merabet O; Pietrosemoli N; Perthame E; Armengaud J; Gaillard JC; Borges-Cardoso V; Daniau M; Legras-Lachuer C; Carnec X; Baize S
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337059
[TBL] [Abstract][Full Text] [Related]
10. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
13. Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.
Schaeffer J; Carnec X; Reynard S; Mateo M; Picard C; Pietrosemoli N; Dillies MA; Baize S
PLoS Pathog; 2018 Nov; 14(11):e1007430. PubMed ID: 30419076
[TBL] [Abstract][Full Text] [Related]
14. Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.
Ye C; de la Torre JC; Martínez-Sobrido L
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669332
[TBL] [Abstract][Full Text] [Related]
15. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
[TBL] [Abstract][Full Text] [Related]
17. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
18. Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques.
Rasmussen AL; Tchitchek N; Safronetz D; Carter VS; Williams CM; Haddock E; Korth MJ; Feldmann H; Katze MG
J Virol; 2015 Mar; 89(5):2543-52. PubMed ID: 25520505
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
Zapata JC; Carrion R; Patterson JL; Crasta O; Zhang Y; Mani S; Jett M; Poonia B; Djavani M; White DM; Lukashevich IS; Salvato MS
PLoS Negl Trop Dis; 2013; 7(9):e2406. PubMed ID: 24069471
[TBL] [Abstract][Full Text] [Related]
20. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
